American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Aurinia Pharmaceuticals Inc. (AUPH)

$16.86 -2.71% NASDAQ: AUPH · 15-min delayed

EDMONTON, A0
Public · NASDAQ: AUPH
128 employees

Visit website Follow

$2.0BMarket cap

$283.1MRevenue · FY2025

$287.2MNet income

128Employees

AUPHNASDAQ

2009IPO

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: AUPH
Employees: 128
IPO date: Oct 21, 2009
Headquarters: #140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: AUPH Nasdaq
SEC CIK: 1600620
LEI: 5299008YP2BW4570ML28
EIN: 981231763
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Aurinia Pharmaceuticals Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/aurinia-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/aurinia-pharmaceuticals-inc.svg" alt="Aurinia Pharmaceuticals Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Aurinia Pharmaceuticals Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $283.1M
Net income: $287.2M
Total assets: $751.6M
Market cap: $2.0B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: AUPH

$16.86 -2.71%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$11.05 $18.62

52-week range

Market cap: $2.0B
Shares outstanding: 117.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 21, 2009

Aurinia Pharmaceuticals Inc. (AUPH) Stock Price

Profitable — net income of $287.2M in FY2025.
Trading 9% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Aurinia Pharmaceuticals Inc..

Write a review

Newsroom

News about Aurinia Pharmaceuticals Inc.

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term Zacks Investment Research · 2026-10-23 · positive Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight GlobeNewswire Inc. · 2026-09-14 · positive 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments GlobeNewswire Inc. · 2026-04-10 · positive New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights GlobeNewswire Inc. · 2025-01-08 · positive Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund’s Disaster Relief Program GlobeNewswire Inc. · 2024-10-02 · positive Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? Zacks Investment Research · 2024-06-17

News & sentiment via Polygon.io

FAQ

Aurinia Pharmaceuticals Inc.: frequently asked questions

Is Aurinia Pharmaceuticals Inc. an American company?

Aurinia Pharmaceuticals Inc. is a US-based company headquartered in Edmonton, A0, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Aurinia Pharmaceuticals Inc. headquartered?

Aurinia Pharmaceuticals Inc. is headquartered in Edmonton, A0, United States.

Is Aurinia Pharmaceuticals Inc. publicly traded?

Yes — Aurinia Pharmaceuticals Inc. is a publicly traded company. Its stock trades under the ticker symbol AUPH on the NASDAQ.

What does Aurinia Pharmaceuticals Inc. do?

Aurinia Pharmaceuticals Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore